TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06214195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
Description: Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
Study: NCT05520073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: Lactobacillus product 1 pack daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C tablet 1 pack daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C tablet 1 pack daily
Study: NCT04868708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Subjects will receive Bevacizumab intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Subjects will receive Paclitaxel intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Subjects will receive Paclitaxel intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Subjects will receive Cisplatin or Carboplatin intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Subjects will receive Cisplatin or Carboplatin intravenously.
Study: NCT06545851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy - constant oxygen flow
Description: During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy - constant oxygen flow
Description: During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy - automatic titrating oxygen flow
Description: During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy - automatic titrating oxygen flow
Description: During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.
Study: NCT05172206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: symptom-focused rehabilitation
Description: Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
Study: NCT05309174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USG-guided iSLN block
Description: Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
Study: NCT04923269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT05341076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
Study: NCT05301101

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
Study: NCT05398731

Intervention type: OTHER
Intervention: Covid_19
Description: Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19

Intervention type: OTHER
Intervention: Covid_19
Description: Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19

Intervention type: OTHER
Intervention: Covid_19
Description: Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19

Intervention type: OTHER
Intervention: Covid_19
Description: Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
Study: NCT05954338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202307
Description: DWC202307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202307
Description: DWC202307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1543
Description: DWJ1543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202216
Description: DWC202216
Study: NCT06385665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded companionship
Description: Accompanying levels are divided into beginner, intermediate and advanced
Study: NCT05870826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiwave locked system laser therapy
Description: High intensity laser therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser therapy
Description: Sham laser therapy
Study: NCT04974645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-SUDs
Description: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.

Intervention type: OTHER
Group type: OTHER
Intervention: Digitally-delivered Psychoeducation
Description: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
Study: NCT06260384

Intervention type: OTHER
Intervention: electrocardiogram
Description: it is a non-invasive study to diagnose criteria of Wolf-Parkinson-Wall syndrome and detect any arrhythmias
Study: NCT01669278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosheath
Description: Flexible sheathed nasopharyngolaryngoscopy
Study: NCT04972071

Intervention type: OTHER
Group type: OTHER
Intervention: Knowledge translation (KT) of the CSRS based practice recommendations
Description: The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
Study: NCT06212232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Description: Application of a new piezoelectric technique in third molar surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Piezoelectric surgery
Description: Application of a new piezoelectric technique in third molar surgery
Study: NCT05371483

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory Blood Pressure Monitoring
Description: Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory Blood Pressure Monitoring
Description: Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory Blood Pressure Monitoring
Description: Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oculo-Cognitive Addition Test (OCAT)
Description: Tracks users' eye movements as they complete a simple mental addition test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oculo-Cognitive Addition Test (OCAT)
Description: Tracks users' eye movements as they complete a simple mental addition test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oculo-Cognitive Addition Test (OCAT)
Description: Tracks users' eye movements as they complete a simple mental addition test.
Study: NCT05172206

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
Study: NCT04687969

Intervention type: DRUG
Intervention: [18F]DCFPyL
Description: will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination

Intervention type: DRUG
Intervention: [18F]DCFPyL
Description: will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination

Intervention type: RADIATION
Intervention: PET/MRI scanner
Description: PET/MRI Scan with \[18F\]DCFPyL as directed by protocol

Intervention type: RADIATION
Intervention: PET/MRI scanner
Description: PET/MRI Scan with \[18F\]DCFPyL as directed by protocol
Study: NCT04760431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles, administered by IV infusion every week until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles, administered by IV infusion every week until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Docetaxel: 75 mg/m2, administered by IV infusion every 3 weeks Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxanes
Description: Docetaxel: 75 mg/m2, administered by IV infusion every 3 weeks Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: Pyrotinib: 400mg po within 30 minutes after a meal, QD, every 3 weeks Neratinib: 240mg po QD, every 3 weeks Tucatinib: 300mg po Q12H
Study: NCT04703972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical assessment (mood relapses identification)
Description: clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
Study: NCT06449482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: three dosage groups were set up, selinexor 60mg QW, 40mg BIW, or 60mg BIW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: cycle 1 100mg d1 200mg d2 400mg d3-28 cycle 2-4 400mg d1-d28
Study: NCT05461092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Pain Trajectory
Description: Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tampa Scale of Kinesiophobia
Description: Questionnaire assessing Kinesiophobia
Study: NCT06449482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 d1-d7 28d/cycle 4 cycles
Study: NCT04720456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Description: The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
Study: NCT05706272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Description: The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The control group will receive care as usual at the matched control primary care centers
Study: NCT05811377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
Study: NCT05372601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relax+
Description: Prebiotics, daily administered

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo, daily administered
Study: NCT05400200

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: questionnary administration
Description: questionary
Study: NCT05336240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Communication 2 Virtual (PCOM2-virtual)
Description: The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Communication Standard (PCOM-standard)
Description: The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
Study: NCT06571123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İnteractive floor
Description: Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
Study: NCT06572566

Intervention type: OTHER
Intervention: Non-invasive examination and assessment.
Description: 1) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.

Intervention type: OTHER
Intervention: Non-invasive examination and assessment.
Description: 1) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
Study: NCT05173519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibond Topical Skin Adhesive
Description: Application of Omnibond topical skin adhesive to close incision following surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Advanced Topical Skin Adhesive
Description: Application of Dermabond topical skin adhesive to close incision following surgery
Study: NCT06058507

Intervention type: DIAGNOSTIC_TEST
Intervention: CT angiography
Description: No intervention was made